Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login


Investigational medicines

Ebola research gets a 280m euro boost from EU and drug industry

European Union (EU) pledges 280 million euros for research to develop Ebola vaccines and diagnostic tests

Source: Greg E Mathieson Sr / Rex Features

New money has been pledged in Europe towards developing Ebola vaccines and diagnostic tests.

The European Union has pledged €280m to a research project that will develop vaccines and diagnostic tests for Ebola.

The money will go to the Innovative Medicines Initiative (IMI), a public-private partnership, with the European Commission contributing €140m and another €140m provided by drug companies.

The European Federation of Pharmaceutical Industries and Associations (EFPIA), in partnership with the IMI, has issued a call for proposals that it hopes will make a “tangible contribution” to global efforts to tackle the current and future Ebola outbreaks.

Known as Ebola+, the first wave of the programme will fund projects in five areas: vaccine development; manufacturing capability; stability of vaccines during transport and storage; deployment and compliance of vaccination regimens; and rapid diagnostic tests.

The deadline for submitting proposals is 10 December 2014. The first projects are expected to begin in early 2015 with further calls for proposals being issued in the coming months.

Carlos Moedas, European commissioner for research, science and innovation, said in a statement: “The EU is determined to help find a solution to Ebola. We are putting our money where our mouth is and boosting EU research on Ebola with an additional €280m. With this funding from Horizon 2020 and our industry partners, we are stepping up the development of new vaccines and medications to help save lives around the world.”


Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2014.20067090

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Drugs of Abuse

    Drugs of Abuse

    A concise, easy-to-read guide for healthcare professionals who encounter drug abuse.

    £38.00Buy now
  • Adverse Drug Reactions

    Adverse Drug Reactions

    A practical guide to the drug reactions that affect particular organ systems, and the management of these reactions.

    £38.00Buy now
  • English Delftware Drug Jars

    English Delftware Drug Jars

    This beautiful book illustrates the art and history of the collection of English delftware drug jars in the Museum of the Royal Pharmaceutical Society of Great Britain.

    £54.00Buy now
  • Paediatric Drug Handling

    Paediatric Drug Handling

    Written for new pharmaceutical scientists, this book provides a background in paediatric pharmacy and a comprehensive introduction to children's medication.

    £33.00Buy now
  • Introduction to Renal Therapeutics

    Introduction to Renal Therapeutics

    Introduction to Renal Therapeutics covers all aspects of drug use in renal failure. Shows the role of the pharmacist in patient care for chronic kidney disease.

    £38.00Buy now
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.